

Xolair® (omalizumab)

When requesting Xolair® (omalizumab), the individual requiring treatment must be diagnosed with the one of the following FDA-approved indications and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indications

Asthma

Xolair is indicated for patients 6 years of age and older with moderate to severe persistent asthma who have a positive skin test or *in vitro* reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids.

Chronic Spontaneous Urticaria

Xolair is indicated for the treatment of adults and adolescents 12 years of age and older with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment.

Chronic Rhinosinusitis with Nasal Polyps

Xolair is indicated for add-on maintenance treatment of chronic rhinosinusitis with nasal polyps in adults patients 18 years of age and older with inadequate response to nasal corticosteroids.

IgE-Mediated Food Allergy

Xolair is indicated for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.

Coverage Guidelines

Asthma

The individual must meet all of the following criteria for initial authorization:

- Has a baseline serum total immunoglobulin E (IgE) level greater than or equal to 30 IU/mL prior to receiving any treatment with Xolair or another monoclonal antibody therapy that may lower IgE levels;
- Has a baseline positive skin test or *in vitro* test (i.e., a blood test) for allergen-specific IgE for one or more perennial aeroallergens and/or for one or more seasonal aeroallergens prior to receiving any treatment with Xolair or another monoclonal antibody therapy that may interfere with allergen testing;
- Has received at least 3 consecutive months of combination therapy with an inhaled corticosteroid and one additional asthma controller/maintenance medication (e.g., monoclonal antibody therapies, inhaled long-acting beta₂-agonists, inhaled long-acting muscarinic antagonists, leukotriene receptor

antagonists, a combination inhaler containing both an inhaled corticosteroid and a long acting beta₂-agonist);

- Asthma is/was uncontrolled prior to starting Xolair or another monoclonal antibody therapy (e.g., Cinqair, Dupixent, Fasenra, Nucala, Tezspire) defined by ONE of the following:
 - o Has experienced two or more asthma exacerbations requiring treatment with systemic corticosteroids in the previous year; OR
 - o Has experienced one or more asthma exacerbation(s) requiring hospitalizations, emergency room visits, or urgent care visits in the previous year; OR
 - o Has a forced expiratory volume in 1 second (FEV₁) less than 80% predicted; OR
 - o Has an FEV₁/forced vital capacity (FVC) less than 0.80; OR
 - o Asthma worsens upon tapering of oral corticosteroid therapy;
- Is 6 years of age or older;
- Xolair is prescribed by or in consultation with an allergist, immunologist, or pulmonologist.

The individual must meet all of the following criteria for re-authorization:

- Has already received at least 4 months of Xolair therapy (*NOTE: Patients who have received less than 4 months of therapy or those who are restarting therapy with Xolair should be considered under initial criteria*);
- Continues to receive therapy with one inhaled corticosteroid (ICS) or one ICS-containing combination inhaler (i.e., Flovent Diskus/HFA, ArmonAir RespiClick, Arnuity);
- Has responded to Xolair therapy (i.e., decreased asthma symptoms or exacerbations; decreased hospitalizations, emergency room visits, urgent care visits, or medical clinic visits due to asthma; decreased reliever/rescue medication use; increased lung function parameters).

Approval duration (initial): 4 months

Approval duration (renewal): 12 months

Chronic Idiopathic Urticaria (Chronic Spontaneous Urticaria)

The individual must meet all of the following criteria for initial authorization:

- Had urticaria for more than 6 weeks, with symptoms present for more than 3 days per week;
- Has experienced inadequate control of symptoms despite treatment with daily non-sedating H₁ antihistamine therapy (i.e., cetirizine, desloratadine, fexofenadine, levocetirizine, loratadine) with doses that have been titrated up to a maximum of four times the standard FDA-approved dose;
- Is 12 years of age or older;
- Xolair is prescribed by or in consultation with an allergist, immunologist, or dermatologist.

The patient must meet both of the following criteria for re-authorization:

- Has already received at least 4 months of Xolair therapy (*NOTE: Patients who have received less than 4 months of therapy or those who are restarting therapy with Xolair should be considered under initial criteria*);
- Has responded to Xolair therapy (i.e., decreased severity of itching, decreased number and/or size of hives).

Approval duration (initial): 4 months

Approval duration (renewal): 12 months

Chronic Rhinosinusitis with Nasal Polyps

The individual must meet all of the following criteria for initial authorization:

- Has a baseline IgE level greater than or equal to 30 IU/mL prior to receiving any treatment with Xolair or another monoclonal antibody therapy that may lower IgE levels;
- Has chronic rhinosinusitis with nasal polyps as evidenced by direct examination, endoscopy, or sinus computed tomography (CT) scan;
- Has experienced two or more of the following symptoms for at least 6 months: nasal congestion, nasal obstruction, nasal discharge, and/or reduction/loss of smell;
- Has received at least 4 weeks of therapy with an intranasal corticosteroid and will continue to receive an intranasal corticosteroid concomitantly with Xolair;
- Meets one of the following:
 - Has received at least one course of treatment with a systemic corticosteroid for 5 days or more within the previous 2 years; OR
 - Has a contraindication to systemic corticosteroid therapy; OR
 - Has had prior surgery for nasal polyps;
- Is 18 years of age or older;
- Xolair is prescribed by or in consultation with an allergist, immunologist, or otolaryngologist (i.e., ear, nose, and throat [ENT] physician specialist).

The individual must meet all of the following criteria for re-authorization:

- Has already received at least 6 months of Xolair therapy (*NOTE: Patients who have received less than 6 months of therapy or those who are restarting therapy with Xolair should be considered under initial criteria*);
- Continues to receive an intranasal corticosteroid therapy;
- Has responded to Xolair therapy (i.e., reduced nasal polyp size, improved nasal congestion, reduced sinus opacification, decreased sino-nasal symptoms, and/or improved sense of smell).

Approval duration (initial): 6 months

Approval duration (renewal): 12 months

IgE-Mediated Food Allergy

The individual must meet all of the following criteria for approval:

- Is one year of age or older;

- Has a baseline IgE level greater than or equal to 30 IU/mL prior to receiving any treatment with Xolair or another monoclonal antibody therapy that may lower IgE levels;
- Has a positive skin prick test (SPT) response to one or more foods;
- Has a positive *in vitro* test (i.e., a blood test) for IgE to one or more foods;
- Has a history of an allergic reaction to a food that met each of the following:
 - o Demonstrated signs and symptoms of a significant systemic allergic reaction (e.g., hives, swelling, wheezing, hypotension, or gastrointestinal symptoms); AND
 - o This reaction occurred within a short period of time following a known ingestion of the food; AND
 - o The prescriber deemed this reaction significant enough to require a prescription for an epinephrine auto-injector
- Xolair will be used in conjunction with a food allergen-avoidant diet;
- Xolair is prescribed by or in consultation with an allergist or immunologist.

Approval duration: 12 months

Dosing Recommendations

Asthma

The recommended dose of Xolair is 75 mg to 375 mg by subcutaneous injection every 2 or 4 weeks based on serum total IgE level measured before the start of treatment and by body weight.

Chronic Spontaneous Urticaria

The recommended dose of Xolair is 150 mg or 300 mg by subcutaneous injection every 4 weeks.

Chronic Rhinosinusitis with Nasal Polyps

The recommended dose of Xolair is 75 mg to 600 mg by subcutaneous injection every 2 or 4 weeks based on serum total IgE level measure before the start of treatment and by body weight.

IgE-Mediated Food Allergy

The recommended dose of Xolair is 75 mg to 600 mg by subcutaneous injection every 2 or 4 weeks based on serum total IgE level measured before the start of treatment and by body weight.

References

1. Xolair® subcutaneous injection [prescribing information]. South San Francisco, CA and East Hanover, NJ: Genentech and Novartis; February 2024.
2. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. *J Allergy Clin Immunol*. 2001;108(2):184-190.
3. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. *J Allergy Clin Immunol*. 2003;111(2):278-284.

4. Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. *Ann Allergy Asthma Immunol*. 2003;91:154-159.
5. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. *Chest*. 2004;125(4):1378-1386.
6. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. *Eur Respir J*. 2001;18:254-261.
7. Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. *Eur Respir J*. 2002;20:73-78.
8. Buhl R, Hanf G, Solèr M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. *Eur Respir J*. 2002;20:1088-1094.
9. Holgate S, Chuchalin A, Herbert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. *Clin Exp Allergy*. 2004;34:632-638.
10. Kulus M, Hebert J, Garcia E, et al. Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma. *Curr Med Res Opin*. 2010;26:1285-1293.
11. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). *Pediatrics*. 2001;108(2).
12. Saini SS, Bindslev-Jensen C, Maurer M, et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. *J Invest Dermatol*. 2015;135:67-75.
13. Maurer M, Rosen K, Hsieh HJ, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. *N Engl J Med*. 2013;368:924-935.
14. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis; 2 randomized phase 3 trials. *J Allergy Clin Immunol*. 2020;146(3):595-605.
15. Wood RA, Togias A, Sicherer SH, et al. Omalizumab for the treatment of multiple food allergies. *N Engl J Med*. 2024 Feb 25. [Epub ahead of print].
16. Global Initiative for Asthma. Global strategy for asthma management and prevention. Updated 2023. Available at: <http://www.ginasthma.org>. Accessed on: March 1, 2024.
17. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J*. 2014;43:343-373.
18. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society Guideline. *Eur Respir J*. 2020;55:1900588.
19. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. *Allergy*. 2022;73:734-766.
20. Rank MA, Chu DK, Bognanni A, et al. Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. *J Allergy Clin Immunol*. 2023;151(2):386-398.
21. Peters AT, Spector S, Hsu J, et al. Diagnosis and management of rhinosinusitis: a practice parameter update. *Ann Allergy Asthma Immunol*. 2014;347-385.
22. Dykewicz MS, Wallace DV, Baroody F, et al. Treatment of seasonal allergic rhinitis: an evidenced-based focused 2017 guideline update. *Ann Allergy Asthma Immunol*. 2017;119(6):489-511.
23. Joint Task Force on Practice Parameters: American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Rhinitis 2020: a practice parameter update. *J Allergy Clin Immunol*. 2020;146:721-767.
24. Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. *Otolaryngol Head Neck Surg*. 2015;152(2S):S1-S39.
25. Chan S, Cornelius V, Cro S, et al. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the ADAPT randomized clinical trial. *JAMA Pediatr*. 2019;174(1):29-37.
26. Holm JG, Agner T, Sand C, et al. Omalizumab for atopic dermatitis: case series and a systematic review of the literature. *Int J Dermatol*. 2017;56(1):18-26.
27. Wang HH, Li YC, Huang YC, et al. Efficacy of omalizumab in patients with atopic dermatitis: a systematic review and meta-analysis. *J Allergy Clin Immunol*. 2016;138(6):1719-1722.
28. Davis DMR, Drucker AM, Alikhan A, et al. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. *J Am Acad Dermatol*. 2024;90(2):E43-E56.
29. Baccelli A, Kocwin M, Parazzini EM, et al. Long-term outcomes of combination biologic therapy in uncontrolled severe asthma: a case study. *J Asthma*. 2023;60(5):1050-1053.
30. Altman MC, Lenington J, Bronson S, et al. Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis. *J Allergy Clin Immunol Pract*. 2017;5(4):1137-1139.
31. Han D, Lee JK. Severe asthma with eosinophilic gastroenteritis effectively managed by mepolizumab and omalizumab. *Ann Allergy Asthma Immunol*. 2018;121(6):742-743.
32. Dedaj R, Unsel L. Case study: a combination of mepolizumab and omalizumab injections for severe asthma. *J Asthma*. 2019;56(5):473-474.
33. Gisondi P, Maurelli M, Costanzo A, et al. The combination of dupilumab with other monoclonal antibodies. *Dermatol Ther (Heidelb)*. 2023;13(1):7-12.

34. Foroughi S, Foster B, Young Kim N, et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. *J Allergy Clin Immunol.* 2007;120(3):594-601.
35. Clayton F, Fang JC, Gleich GJ, et al. Eosinophilic esophagitis in adults is associated with IgG4 and not mediated by IgE. *Gastroenterology.* 2014;147:602-609.
36. Fang JC, Hilden K, Gleich GJ, et al. A pilot study of the treatment of eosinophilic esophagitis with omalizumab. *Gastroenterology.* 2011;140(5):S-235.
37. Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis. *Am J Gastroenterol.* 2013;108(5):679-692.
38. Hirano I, Chan ES, Rank MA, et al. AGA Institute and Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. *Gastroenterology.* 2020;158(6):1776-1786.
39. Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy [letter]. *J Allergy Clin Immunol.* 2004;113(2):360-361.